These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 8104041)

  • 41. Sleep onset REM periods in schizophrenic patients.
    Taylor SF; Tandon R; Shipley JE; Eiser AS; Goodson J
    Biol Psychiatry; 1991 Jul; 30(2):205-9. PubMed ID: 1912111
    [No Abstract]   [Full Text] [Related]  

  • 42. Long-term effects of risperidone versus haloperidol on verbal memory, attention, and symptomatology in schizophrenia.
    Rémillard S; Pourcher E; Cohen H
    J Int Neuropsychol Soc; 2008 Jan; 14(1):110-8. PubMed ID: 18078537
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Serum amino acids, central monoamines, and hormones in drug-naive, drug-free, and neuroleptic-treated schizophrenic patients and healthy subjects.
    Rao ML; Gross G; Strebel B; Bräunig P; Huber G; Klosterkötter J
    Psychiatry Res; 1990 Dec; 34(3):243-57. PubMed ID: 1981623
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effects of neuroleptic reduction in schizophrenic outpatients receiving high doses.
    Leblanc G; Cormier H; Gagné MA; Vaillancourt S
    Can J Psychiatry; 1994 May; 39(4):223-9. PubMed ID: 7913872
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Attentional dysfunctions in neuroleptic-naive and neuroleptic-withdrawn schizophrenic patients and their siblings.
    Finkelstein JR; Cannon TD; Gur RE; Gur RC; Moberg P
    J Abnorm Psychol; 1997 May; 106(2):203-12. PubMed ID: 9131840
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The positive-negative distinction in drug-free schizophrenic patients. Stability, response to neuroleptics, and prognostic significance.
    Kay SR; Singh MM
    Arch Gen Psychiatry; 1989 Aug; 46(8):711-8. PubMed ID: 2568824
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Nonlinear analysis of sleep EEG data in schizophrenia: calculation of the principal Lyapunov exponent.
    Röschke J; Fell J; Beckmann P
    Psychiatry Res; 1995 Apr; 56(3):257-69. PubMed ID: 7568548
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Combination alprazolam-neuroleptic treatment of the positive and negative symptoms of schizophrenia.
    Wolkowitz OM; Pickar D; Doran AR; Breier A; Tarell J; Paul SM
    Am J Psychiatry; 1986 Jan; 143(1):85-7. PubMed ID: 2867690
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Clinical, EEG mapping and psychometric studies in negative schizophrenia: comparative trials with amisulpride and fluphenazine.
    Saletu B; Küfferle B; Grünberger J; Földes P; Topitz A; Anderer P
    Neuropsychobiology; 1994; 29(3):125-35. PubMed ID: 7912819
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Clinical predictors of relapse following neuroleptic withdrawal.
    Buchanan RW; Kirkpatrick B; Summerfelt A; Hanlon TE; Levine J; Carpenter WT
    Biol Psychiatry; 1992 Jul; 32(1):72-8. PubMed ID: 1356490
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Risperidone versus haloperidol in the treatment of chronic schizophrenic inpatients: a multicentre double-blind comparative study.
    Claus A; Bollen J; De Cuyper H; Eneman M; Malfroid M; Peuskens J; Heylen S
    Acta Psychiatr Scand; 1992 Apr; 85(4):295-305. PubMed ID: 1375801
    [TBL] [Abstract][Full Text] [Related]  

  • 52. EEG sleep patterns in schizophrenic patients undergoing hemodialysis.
    Gillin JC; Schulz SC; van Kammen DP; Balow JE; Bunney WE
    Psychiatry Res; 1981 Dec; 5(3):287-91. PubMed ID: 7034027
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Recent and remote memory dissociation: medication effects and hippocampal function in schizophrenia.
    Gilbertson MW; van Kammen DP
    Biol Psychiatry; 1997 Oct; 42(7):585-95. PubMed ID: 9376455
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The effects of Ginkgo biloba extract added to haloperidol on peripheral T cell subsets in drug-free schizophrenia: a double-blind, placebo-controlled trial.
    Zhang XY; Zhou DF; Cao LY; Wu GY
    Psychopharmacology (Berl); 2006 Sep; 188(1):12-7. PubMed ID: 16906395
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Prediction of relapse in schizophrenia.
    Lieberman JA; Kane JM; Sarantakos S; Gadaleta D; Woerner M; Alvir J; Ramos-Lorenzi J
    Arch Gen Psychiatry; 1987 Jul; 44(7):597-603. PubMed ID: 2886110
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Neuroleptic responsivity of negative and positive symptoms in schizophrenia.
    Breier A; Wolkowitz OM; Doran AR; Roy A; Boronow J; Hommer DW; Pickar D
    Am J Psychiatry; 1987 Dec; 144(12):1549-55. PubMed ID: 3688278
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Electroencephalographic sleep in young, never-medicated schizophrenics. A comparison with delusional and nondelusional depressives and with healthy controls.
    Ganguli R; Reynolds CF; Kupfer DJ
    Arch Gen Psychiatry; 1987 Jan; 44(1):36-44. PubMed ID: 3800582
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Novel Augmentation Strategies in Major Depression.
    Martiny K
    Dan Med J; 2017 Apr; 64(4):. PubMed ID: 28385173
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Short-term prospective comparison of prepulse inhibition between schizophrenic patients and healthy controls.
    Preuss UW; Zimmermann J; Watzke S; Langosch J; Siafarikas N; Wong JW; Hamm A; Weike A
    Pharmacopsychiatry; 2011 May; 44(3):102-8. PubMed ID: 21432751
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Insomnia as a predictor for symptom worsening following antipsychotic withdrawal in schizophrenia.
    Chemerinski E; Ho BC; Flaum M; Arndt S; Fleming F; Andreasen NC
    Compr Psychiatry; 2002; 43(5):393-6. PubMed ID: 12216015
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.